Formulation Development
Greenwich LifeSciences Announces Positive Immune Response Data From Phase 3 Clinical Trial
Greenwich LifeSciences, Inc. recently announced the following update on FLAMINGO-01 open label immune response data. FLAMINGO-01 Immune Response Data Summary The Company has analyzed the…
Antag Therapeutics Initiates Phase 1a Trial of a First-in-Class GIPR Antagonist to Address Key Gaps in Obesity Treatment
Antag Therapeutics recently announced the initiation of its first-in-human Phase 1 clinical trial evaluating AT-7687, a first-in-class Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) antagonist. AT-7687 is…
Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial
Tiziana Life Sciences, Ltd. recently announced dosing has commenced at Johns Hopkins University (JHU) Autoimmunity Center of Excellence, the third clinical site in its Phase 2…
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval
Denali Therapeutics Inc. recently announced the company’s initiation of a rolling submission of a biologics license application (BLA) for accelerated approval of tividenofusp alfa for…
Atsena Therapeutics Announces $150M to Further Advance Ocular Gene Therapy Programs
Atsena Therapeutics recently announced the successful close of an oversubscribed $150-million Series C financing. The financing was led by Bain Capital’s Life Sciences team, with…
Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program
Revive Therapeutics Ltd. recently announce that further to its press release dated March 3, 2025, it has entered into an asset purchase agreement dated March…
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 & Nivolumab Plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients
Candel Therapeutics, Inc. recently announced the publication of a manuscript reporting the results of a Phase 1b clinical trial exploring safety and tolerability of the…
GRIN Therapeutics Receives Priority Medicines Designation From EMA for Radiprodil in the Treatment of GRIN-Related Neurodevelopmental Disorder
GRIN Therapeutics, Inc. recently announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to radiprodil, the company’s investigational, potent negative allosteric…
Moleculin Doses First Patient in Pivotal Adaptive Phase 3 MIRACLE Trial
Moleculin Biotech, Inc. recently announced the first patient has been dosed in its Phase 3 pivotal trial evaluating Annamycin in combination with Cytarabine (also known…
DDL Launches New GMP Lab for Drug Delivery Testing
DDL, a leading provider of package, product, and material testing services, recently announce the opening of a new Good Manufacturing Practice (GMP) laboratory dedicated to…
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
Gyre Therapeutics recently announced that the National Medical Products Administration (NMPA) of the People’s Republic of China (PRC) has approved its clinical trial application for…
Trethera Treats a Late Stage, Heavily Pretreated Amyotrophic Lateral Sclerosis Patient With TRE 515
Trethera Corporation recently announced clinical results from treating a patient with ALS (amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease) with TRE-515 under the…
Apollomics & LaunXP Announce Development & Commercialization Agreement for Vebreltinib
Apollomics Inc. and LaunXP International Co., Ltd. recently announced the parties have entered into an agreement for the development and commercialization in Asia (excluding mainland…
NeOnc Technologies Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas
NeOnc Technologies Holdings, Inc. recently announced the US FDA has granted Rare Pediatric Disease Designation (RPDD) to perillyl alcohol (NEO100) for the treatment of pediatric-type…
CERo Therapeutics Holdings Receives FDA Clearance of Second Investigational NDA to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors
CERo Therapeutics Holdings, Inc. recently announced it has received clearance by the US FDA for a second Investigational New Drug (IND) application for lead compound…
Conduit Pharmaceuticals Receives US Patent Approval for Its Lead Asset Targeting Autoimmune Diseases
Conduit Pharmaceuticals Inc. recently announced that the United States Patent and Trademark Office (USPTO) has granted the composition of matter patent for its lead asset,…
LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100
LIXTE Biotechnology Holdings, Inc recently announced it will conduct a new pre-clinical study in collaboration with Netherlands Cancer Institute (NKI) to test whether “initiated” cells that…
Lexicon Pharmaceuticals Announces Exclusive License Agreement With Novo Nordisk
Lexicon Pharmaceuticals, Inc. recently announced it has entered into an exclusive license agreement with Novo Nordisk A/S for LX9851, a first-in-class, oral non-incretin development candidate…
Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data
Silexion Therapeutics Corp. recently announced an expanded development plan for its next-generation siRNA candidate, SIL204. This strategy integrates systemic administration to target metastatic progression with…
Ocean Biomedical Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 & PD1 for Enhanced Tumor Cell Cytotoxicity
Ocean Biomedical, Inc. recently announced the China National Intellectual Property Administration (CNIPA) has granted a notice of grant on patent right for its bispecific antibodies…
